PIM1 inhibition effectively enhances plerixafor-induced HSC mobilization by counteracting CXCR4 upregulation and blocking CXCL12 secretion

Leukemia. 2019 May;33(5):1296-1301. doi: 10.1038/s41375-019-0428-6. Epub 2019 Feb 28.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Chemokine CXCL12 / biosynthesis*
  • Hematopoietic Stem Cell Mobilization* / methods
  • Hematopoietic Stem Cells / drug effects*
  • Hematopoietic Stem Cells / metabolism*
  • Heterocyclic Compounds / administration & dosage
  • Heterocyclic Compounds / pharmacology*
  • Mice
  • Proto-Oncogene Proteins c-pim-1 / antagonists & inhibitors*
  • Receptors, CXCR4 / antagonists & inhibitors*

Substances

  • CXCR4 protein, mouse
  • Chemokine CXCL12
  • Cxcl12 protein, mouse
  • Heterocyclic Compounds
  • Receptors, CXCR4
  • Pim1 protein, mouse
  • Proto-Oncogene Proteins c-pim-1
  • plerixafor